CHICAGO, March 21, 2013 (GLOBE NEWSWIRE) -- MAKO Surgical Corp., developer of human-interactive surgical robotic arm technology used to achieve accuracy in treating osteoarthritic disease, today announced the first results from a ten-year, prospective, randomized controlled trial evaluating the accuracy of unicompartmental knee arthroplasty (UKA) implant positioning, with and without robotic arm surgical assistance. Early results from this pivotal study are compelling, showing that robotic arm assisted UKA enhanced the accuracy of implant placement and decreased the levels of pain.
Performed under the guidance of orthopaedic surgeons Mark Blyth, M.D., Bryn Jones, M.D., Angus Maclean, M.D, and Iain Anthony, Ph.D., and Phil Rowe, Ph.D., at the Glasgow Royal Infirmary and the University of Strathclyde, in Glasgow, Scotland, the trial compared implant placement accuracy in patients receiving MAKO's RESTORIS ® MCK implants using MAKO's RIO ® Robotic Arm Interactive Orthopedic System to patients receiving manual placement of the Oxford ® Partial Knee implant from Biomet Orthopedics. One hundred patients have been enrolled in the study and randomly assigned (50 MAKO vs. 50 Oxford) to receive UKA with or without the aid of robotic arm assistance. The three-month results from 50 patients in each group also assessed early clinical outcomes such as patient reported post-operative pain levels and satisfaction. It is anticipated the trial will ultimately have 75 patients in each group. The patients will be tracked for ten years post-operatively.
"The early results are encouraging, as the data show more accurate component placement, as well as considerably lower self-reported post-operative pain levels out to six weeks," said Dr. Blyth. "The early results suggest that robotic arm assisted UKA with the RIO system greatly enhances the accuracy of implant placement, which can be achieved with only minimal deviation from the pre-operative plan."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts